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         Introduction 
Thyroid carcinomas represent about 90% of endocrine 
malignancies (1); their are divided into papillary carcinoma 
(PTC), follicular carcinoma (FC), medullary thyroid carcinoma 
(MTC), anaplastic thyroid carcinoma (ATC) (2).  
The papillary thyroid carcinoma (PTC) is the most common 
malignant thyroid tumor, representing 80-90% of thyroid 
malignancies (1, 2); it is the more frequent in childhood and < 
50 years (2). 
 The data collected at the Surveillance Epidemiology and End-
Results Cancer Registries program (SEER) indicate an annual 
average prevalence of thyroid carcinoma of 6.6/100.000 with an 
annual increase > 5% in the period 1975-2002. This increase is 
mainly due to an improved diagnostic histopathology with a 
more frequent use the cytological diagnosis on fine needle 
byopsy (2). Furthermore, between 1988 and 2002, a 49% 
increase in tumors equal to or less than 1 cm was noted; it has 
been postulated that at least part of this rise of papillary thyroid 
microcarcinoma (PTMC) is related to increased detection 
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primarily due to the wide use of thyroid ultrasound, which 
allows the detection of small nonpalpable nodules (3).  
The papillary thyroid microcarcinoma (PTMC), according to the 
World Health Organization (WHO), is defined a tumor mesuring 
1 cm or less in diameter (1, 3, 4, 5, 6), it may be solitary, or 
multiple microfoci may be present (3).  
In 1997, Moosa and Mazzaferri defined ―occult thyroid 
carcinoma ‖as an ―unpalpable thyroid carcinoma that is 
generally smaller than 1 cm‖ (7). A more precise definition of 
size is used by Stedman‘s Medical Dictionary (2006), where 
occult papillary carcinoma of the thyroid is described as 
microcarcinoma of the thyroid or microscopic papillary 
carcinoma of the thyroid, usually well encapsulated and 
measuring less than 5 mm in diameter (7,8).  
A combination is used in the WHO (World Health Organization) 
classification system, where papillary thyroid microcarcinoma 
(PTMC), as mentioned, is defined as ―papillary carcinoma 
measuring 1cm or less in maximal diameter while other clinico-
pathological features, such as metastasis to regional lymph 
nodes and/or distant organs as well as extrathyroid extension, 
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are not considered‖ (9). 
The reported prevalence of multifocality appears to be present in 
30-40% of cases, whereas bilateral disease is found in 
approximately 20% of involved glands.  Cervical lymph node 
adenopathy is discovered in 25-43% of patients with PTMC. 
Extrathyroidal extension is noted in about 15-21%, whereas 
vascular invasion may be present in approximately 3.5%. 
Distant metastases occur unfrequently at a rate of 1-2,8% (3). 
 It could be defined as a thyroid incidentaloma, in fact it is 
occasionally identified at US of the neck performed for other 
reasons but its diagnosis is often incidental (2,3).  
Autopsy studies have revealed that the occurrence of 
microcarcinoma, primarily foci of PTC, ranges between 6 and 
36% according some authors (3) and 0.01% in USA and 35.6% 
in Finland (the highest value reported in the literature) according 
to other authors (10). 
In Western countries and in Japan the percentage of papillary 
thyroid carcinoma is increasing, from 78.4% thirty years ago to 
93%, registered by the Japanese Society of Thyroid Surgeons 
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(JSTS), in 2004. A similar situation has been reported in Western 
countries, where, in 2002, papillary carcinoma comprised 
85.3%. The prevalence of incidentally detected PTMC found at 
autopsy and from clinical studies was 100-1000-fold higher than 
the incidence of clinical cancer (11,12). This finding strongly 
suggests that most papillary microcarcinomas remain latent and 
do not become clinically apparent. The determination of clinical 
and especially molecular parameters which would define a small 
group of PTMC with an aggressive biological behaviour is 
foundamental (7).  
The annual rate mortality of PTMC is between 0.4-2.8 and 0.2-
12/100.000, respectively, for women and men (2).  
The clinical behavior of PTMC is usually indolent as 
demonstrated by recent literature; in fact in a recent work, Hoon 
Y.K et al., emphasizes that one series of 93% of patients were 
free of disease during a follow-up of 3-23 years, with a mean of 
6.3 years, and there were no distant metasteses. 
However, rarely PTMC may have aggressive behavior with 
locoreginal recurrence and cervical lymph node metastases. The 
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lack of long-term prospective randomized studies makes it very 
difficult to establish which therapeuthic approach is better and 
explains the present uncertainty and controversies for the 
management of PTMC (1). 
Its etiology is the result of complex genetic and environmental 
factors interaction in individuals at risk (2).  
Probably the most important risk factor is genetic predisposition, 
which is supported by the fact that the prevalence in the 
Japanese population exposed to the radiation during the bomb 
attack on Hiroshima and Nagasaki (11.3-28.4%)  (13,14,15) and 
in the Japanese population staying in Hawaii, without the 
radiation exposure (24%)  (15,16), is similar. 
In the literature, several critical genetic alterations, associated 
with development of specific thyroid tumour types, have been 
described. The three types of genetic alteration in the Mitogen-
activated Protein Kinase (MAPK) pathway, including RET 
rearrangement and Ras and BRAF mutation, are present in 
approximately 70% of PTCs (17). 
In a recent study the authors (18) showed that the PTMC had 
clinical and pathological factors related to prognosis, evaluated 
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with multivariate analysis (18).    
The aggressive behavior of PTMC may be related to the 
molecular alterations.  
Starting with an analysis of the literature and of our experience 
we want analyze the association betwen aggressiveness 
indicators (extracapsular spread, metastatic lymph nodes) and 
prognostic factors (age, tumor size, uni/multifocal disease,) in a 
high prevalence of goiter area. 
 
Risk factors for thyroid cancer 
Iodine deficiency 
Iodine intake is mentioned as an important environmental factor. 
A wide range of variants has been found in different parts of the 
world. In areas with sufficient iodine intake, the incidence of 
thyroid cancer is higher and a predominance of papillary 
carcinoma has been mentioned. In 2005, Kovacs et al. (11) 
published results of a study, where consecutive series of 
autopsies were performed in Hungary in two areas with different 
iodine uptake (19). They concluded, that the prevalence of 
microcarcinomas was not related to iodine intake, because from 
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222 thyroids examined in an iodine deficient group and from 
221 thyroids in an iodine sufficient group, the prevalence was 
only 4.74%, with respect to 4.52% (11).  
 
Exposure to radiation 
The thyroid gland is highly sensitive to radiation inducing 
oncogenesis and both types of radiation, external or internal 
(delivered from radioiodine), are the most prominent factors in 
the development of thyroid cancer. The most vulnerable is the 
thyroid gland in children, which was clearly documented in 
Belarus et in Ukraine, in connection with the Chernobyl 
accident (7). 
The incidence of thyroid cancer, in children, was less than 1 per 
million, per year, before the accident, but after the accident 
increased, in certain areas, to 100 cases per million per year. 
Surprisingly, in the Chernobyl region, a big difference was 
found in children, exposed to radiation in the age group younger 
than 3 years and those exposed before birth (in utero), born after 
the accident. Fifteen years after the accident, in the first group, 
33 cases of thyroid cancer were found (out of 9472 children), 
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compared to no cases in the group exposed in utero (out of 
12129 children) (7). 
 
Environmental factors in Sicily 
In a recent study Pellegriti et al. have reported a substantially 
higher incidence rate of thyroid cancer in the Catania province 
of Sicily than in other Sicilian provinces and in other parts of 
Italy. They also explored associations of a range of possible risk 
factors for thyroid cancer with the presence of the volcano 
Mount Etna (which is in close proximity to the town of Catania) 
(20).The incidence rates of thyroid cancer  is increasing more 
rapidly than that of other cancers in the United States and its 
incidence is increasing in many other countries, including 
France and Italy. The average incidence of thyroid cancer among 
women and men is 14.1 and 4.9 diagnoses per 100.000 residents 
per year, respectively, in the white population of the United 
States and 12.9 and 5.0 diagnoses per 100.000 residents per 
year, respectively, in Europe. In Italy, the average incidence 
among women and men is 15.5 and 5.2 diagnoses per 100.000 
 10 
residents per year, respectively. Many experts, as mentioned, 
attribute this increasing incidence to more intensive and 
sensitive diagnostic procedures to detect thyroid nodules and to 
diagnose microcarcinomas. Environmental carcinogens 
associated with an industrialized lifestyle might contribute to the 
increasing thyroid cancer incidence. Until now, however, the 
only environmental factors that have been strongly associated 
with thyroid cancer are exposure to radiation and iodine 
deficiency . An increased incidence of thyroid cancer has also 
been reported in volcanic areas with basaltic characteristics, 
such as the volcanic regions of Iceland and Hawaii . The Mt 
Etna volcano in Sicily also has basaltic characteristics and hosts 
a major aquifer that provides drinking water to more than 
750.000 inhabitants and irrigation to large agricultural areas 
nearby. Water from this aquifer and the volcanic soil undergo a 
magmatic-type interaction, in which excess CO2 in volcanic gas 
leads to acidification of water and to leaching of chemicals from 
the basalt rock, especially on the lower south-southwestern and 
eastern flanks of the volcano. Various elements and chemicals 
(including HCO3, SO4, calcium, fluoride, chloride, magnesium, 
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boron, manganese, iron, and vanadium and their salts and also 
222
radon) are often increased in water samples from various 
sources of this volcanic aquifer, as reported in studies of water 
samples in other volcanic areas. The Sicily Island has rural and 
urban areas, industrial and nonindustrial areas, areas of low and 
adequate iodine intake, volcanic and nonvolcanic areas, and a 
homogenous population; thus, Sicily is a favorable setting for 
the evaluation of environmental influences on thyroid cancer 
etiology. 
This data are collected in The Sicilian Regional Registry for 
Thyroid Cancer; it was instituted in January 2002 (21). 
           
        BRAF 
BRAF gene encodes a protein belonging to the family of serine-
threonine kinases, activator of mitogen-activated protein kinase 
(MAPK) with a high affinity for MEK1 and MEK2, MAP 
kinases,  leading to their phosphorylation more efficiently than 
other RAF isoforms. 
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MAPKs respond to mitogenic extracellular stimuli and regulate 
gene expression, mitosis, differentiation, proliferation, and cell 
servival/apoptosis (2). 
The MAPK pathway is activated by signals from a variety of 
cell surface receptors and growth factors (22). 
MEK and MEK2 activate  the serine/threonine specific protein 
kinases ERK1 and ERK2. Activated ERKs are pleiotropic 
effectors of cell physiology and play an important role in the 
control of gene expression involved in the division cycle, 
apoptosis, cell differentiation, and cell migration.  
BRAF mutation is the most common genetic alteration found in 
PTCs (approximately 45% of these tumors); their mutation is 
present in 40-70% of PTCs with higher percentage of positivity 
in more aggressive variants such as ― tall cell ‖ dedifferentiated 
forms (2). 
This mutation is detected in 15.8%–52% of PTMC cases (5).  
In particular, the genetic alteration (point mutation) with the 
higher prevalence in classical PTCs involves the nucleotide 
1799 determining a valine-glutamate substituction at amino acid 
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residue 600 (V600E) with consequent activation of BRAF 
kinase that results in a contiuous  phosphorylation of MEK and 
MAPK pathway effectors. Such  a  mutation is very rare in FTC 
(23,24, 25). 
The characteristics of aggressiveness of PTCs, such as 
extrathyroidal extension, advanced presentation, presence of 
lymph node, or distant metastases have been associated in many 
studies with presence of BRAF mutation (26, 27).      
In the studies on transgenic mice with thyroid-specific 
expression of BRAF V600E, they developed a PTC with 
invasion of blood vessels, thyroid capsule, and perithyroid 
skeletal muscle. These characteristics are all features of 
aggressiveness , demonstrating a progression to poorly 
differentiated thyroid carcinomas (2). 
The BRAF mutation plays a fundamental role in progression, 
invasiveness and recurrence of PTC; it is also associated with 
overexpression of the Vascular Endothelial Growth Factor 
(VEGF) (28), which is a strong angiogenic protumour molecule 
that plays a critical role in human cancer progression and 
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invasion (29) . The explanation for this proangiogenic BRAF – 
VEGF association is in the unique molecular mechanism, when 
BRAF mutation promotes VEGF overexpression and inhibition 
of Tissue Inhibitor of Metalloproteinases-3 (TIMP3) (30).  
TIMP3 is the tumour inhibitor, which suppresses tumour 
growth, angiogenesis, invasion and metastasis by preventing the 
interstitial matrix destruction promoted by matrix 
metalloproteinase 3 (MMP-3). Moreover, BRAF mutation, in 
the primary PTC, is associated with loss of radioiodine avidity 
in the recurrent tumour (2). 
The BRAF mutation in studies from Korea reported an 
unusually high  prevalence in both PTC (80-90%) and PTMC 
(65%) (7). 
Hoon You Kim et al. analyzed the gene expression profiles of 
PTMC, never been reported before, and compared those with 
PTC. Most of the commonly up-regulated and down-regulated 
genes in PTMC were functionally associated cells adhesion and 
cells-metiated immumity. PTMC and PTC show no difference in 
gene expression level.  For the authors, thus, the PTMC should 
not be considered as the simple occult indolent cancer but as the 
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earlier stage of diseases with evolves into PTC (1).  
Was recently reported that BRAF mutations enhance the 
capacity of BRAF mutated cells to proliferate and transform. It 
has also been suggested that lymph node metastases of papillary 
cancer are accompanied by a new BRAF mutation, different 
from that observed in the matched primary thyroid cancer, 
confirming the progression model of cancer where metastatic 
foci have a new mutational event . These results suggesting that 
PTMC harboring an activating mutation of the gene for BRAF 
might have a more aggressive behavior have not been confirmed 
by another study in Korean patients (10).  
           
          Materials and Methods 
We performed this study from the Service of Endocrine Surgery, 
Unit of General and Emergency  Surgery, Department of 
General, Emergency and Transplant Surgery, University of 
Palermo (Italy), in which, from january 2003 and december 
2010, 1211 total thyroidectomies or completion thyroidectomies 
were performed. Medical records were examined and 424 
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malignancies were found. Off all, 343 were papillary 
carcinomas. Among them, 141 were ≤ 1 cm. The preoperative 
diagnosis was done with systematic use of ultrasonography 
integrated with color-Doppler. Ultrasonographic criteria for 
suspected diagnosis of PTMC were: microcalciﬁcations; 
hypoechoic pattern; increased nodular vascularity; inﬁltrative 
margins (no "halo sign"); taller than wide on transverse view. All 
suspected nodules were studied with a Ultrasound-Guided Fine-
Needle Aspiration Biopsy (FNAB); the samples were analyzed 
for cytology. Cytopathological findings were classified 
according to Bethesda system (31) (Tab. 1).  
Table 1:The Bethesda System for Reporting Thyroid Cytopathology 
I. Nondiagnostic or Unsatisfactory 
                    Cyst fluid only 
                  Other (obscuring blood, clotting artifact, etc) 
II. Benign 
                    Consistent with a benign follicular nodule (includes adenomatoid nodule, colloid nodule, etc) 
                    Consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical context 
                    Consistent with granulomatous (subacute) thyroiditis 
                   Other 
III. Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance 
           IV.     Follicular Neoplasm or Suspicious for a Follicular Neoplasm 
    Specify if Hürthle cell (oncocytic) type 
V. Suspicious for Malignancy 
                     Suspicious for papillary carcinoma 
                     Suspicious for medullary carcinoma 
                     Suspicious for metastatic carcinoma 
                     Suspicious for lymphoma 
    Other 
VI. Malignant 
                    Papillary thyroid carcinoma 
                    Poorly differentiated carcinoma 
                    Medullary thyroid carcinoma 
                    Undifferentiated (anaplastic) carcinoma 
                    Squamous cell carcinoma 
                    Carcinoma with mixed features (specify) 
                    Metastatic carcinoma 
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                    Non-Hodgkin lymphoma 
   Other 
In the patients treated  since 2006, if a fine-needle aspiration 
biopsy had been preoperatively performed, the B-RAF V600E 
were investigated in the sample. The pellet was centrifugated 
and the genomic DNA was drawn out using a Quiagen 
DNAeasy Tissue Kit according to the manufacturer‘s protocol 
(Qiagen, Hilden, Germany). BRAFV600E mutation was 
detected by real-time allele-specific amplification as described 
elsewhere (32). As described in the literature (32) amplification 
was performed with a Lightcycler (Roche Diagnostics GmbH, 
Mannheim, Germany), and fluorescence was measured. After 
completion of the cycling process, samples were subjected to 
melting curve analysis. Positive results were further confirmed 
using a B-RAF Mutector Single-Well Test Kit (Trimgen, Tebu-
Bio, Milan, Italy), following the manufacturer‘s instructions. 
According to original paper of Pizzolanti and coll., cases in 
which the genotype ratio (absorbance from sample=absorbance 
from wild type) was ≥2 were interpreted as mutant (33). 
Genomic DNA was extracted using the QIAamp Tissue Kit 
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(Qiagen, Hilden, Germany) with the standard protocol, and 
BRAF mutation detected as above described. RNA extraction 
from ex vivo thyroid nodules . After surgical resection, thyroid 
samples from nodules obtained by means of careful 
identification by an experienced pathologist and corresponding 
to the biopsied nodule were quickly stored in RNA later (Sigma, 
Milan, Italy) and stored at  - 20°C until use. Samples were 
further processed with the RNAEasy Mini Kit (Qiagen, Milan, 
Italy) for RNA extraction, following the manufacturer‘s 
instructions.  The correspondance between cytologc and 
histologic findings in terms of B-RAF V600E is well known 
(32). 
The diagnosis was defined 34 times preoperatively, in 107 cases 
was incidental. 
PTMC was defined as incidental when it was found on the 
surgical histology samples from patients who had thyroid 
surgery for non-malignant thyroid disorders;  it  was described 
as nonincidental when the tumor was diagnosed preoperatively 
on the basis of fine-needle aspiration biopsy. In our series, no 
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PTMC were diagnosed by means of cervical lymph-node or 
distant  metastases. In mcrocarcinomas incidentally diagnosed, 
the indications for thyroidectomy were compressive symptoms 
(46 patients) or toxic goiter (27 patients). 
Total thyroidectomy was defined as total bilateral extracapsular 
thyroidectomy.  
When the diagnosis was estabished preoperatively or strongly 
suspected intraoperatively,  because of suspect thyroid nodule 
together with enlarged lymph nodes in the VI level and/or in 
lateral compartment were found, a systematic compartment-
oriented lymph-node dissection was performed. Central 
compartment lymph-node dissection is defined by complete 
level VI dissection, and lateral neck lymph-node dissection is a 
level II to level V dissection.  
Tumors were defined as multifocal if two or more tumor foci 
were found in one (unilateral) or both (bilateral) thyroid lobes, 
and the largest tumor dimension was used for statistical analysis. 
All patients in whom a PTMC was found in histological sample, 
were submitted to postoperative (2-4 months) ablation of thyroid 
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residual. 
According to literature (18), the criteria for successful 131I 
thyroid residual postoperative ablation were defined as the 
disappearance of any visible radioiodine uptake in the thyroid 
bed, and a overall radioiodine neck uptake <1%, and 
undetectable serum thyroglobulin off levothyroxine after 
obtaining a serum thyrotropin level (TSH) ≥30 IU/ml. 
All patients in whom a diagnosis of papillary thyroid 
microcarcinoma had been previously made were considered for 
this study. Follow-up evaluation was obtained by outpatient 
consultation and/or telephone interview. 96 patients accepted the 
interwiev and were enrolled in the trial. On the contrary 45 
patients were non found, or refused the clinical study. In patients 
enrolled age, sex, type of diagnosis, (incidental or 
nonincidental), autoimmune thyroid disorders, (Graves‘ disease, 
Hashimoto's thyroiditis), type of lymph-node dissection, thyroid 
volume, tumor size, tumor multifocality, extrathyroidal tumor 
extension and tumor–node–metastases (TNM) staging were 
investigated.  
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As the B-RAFV600E was available since 2006, the patients 
were divided in two groups: 2003-2005 (34 patients), in wich 
prognostic factors such as  age, tumor size, uni/multifocal 
disease, were evaluated; and 2006-2010 (62 patients) in wich 
search of B-Raf mutation in tumoral tissue were evaluated 
together with the previous. We evaluated the association 
between these indicators  and aggressiveness indicators such as 
extracapsular spread, metastatic lymph nodes (if a central neck 
dissection was performed) and tumour recurrence, defined as 
immediate or late 131I residual ablation. 
The data were collected in currently available data base 
(Microsoft Excel® for Mac, version 12.1.0 - 080409). 
 
Results 
Of 96 patients, 76% were females and 22,9% men; their medium 
age was 50,4. 
The recurrencies rate was 8,3% (8 patients). The cancer was 
unifocal in 85 patients (88,5%) and bifocal in 11 patients 
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(11,5%); the capsule invasion in the unifocals was 86,5% (83 
patients) and in the bifocals 12,5% (12 patients). 
9 patients  (9,4%) had lymph node positive for cancer and 18 
(18,8%) negative; in 69 patients (71,9%) the lymph node have 
not been evaluated. 
The BRAF-V600E mutation was detected in 33 patients; of 
these in 26 (27,1% ) the mutation was absent and in 7 (7,3%) 
was present; the BRAF mutation was not evalueted in  65 
patients (65,6%) (Tab. 2).  
There were no recurrences in the cancer < 3 mm but 2 (3,8%) in 
the cancers between 5-6 mm; 3 (11,5%) in the cancers between 
6-7 mm and 4 (36,4%) in those > 7 mm. The p-Value, calculated 
with Chi-square, was < 0,001. The recurrences in the patients 
with capsular invasion were in 2/83 (2,4%) of unifocals and in 
6/12 (50%) of bifocals. The p-Value, calculated with Fisher‘s 
exact test, was  < 0,001. The recurrences in the unifocals cancers 
were 6/85 patients (7,1%) and 2/11 patients (18,2%) in the 
multifocals. The p-Value was 0,23. 
The recurrences in the patients with lymph nodes positives were 
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3/9 (33,3%) and 4/18 (22,2%) in the patients with lymph nodes 
negatives with p-Value < 0.001. 
The BRAF was in 3/7 recurrences (42,9%) with p-Value < 0.01.  
The BRAF was present in 3/7 (42,9%) patients. The tests used 
for statistical analys of recurrences in the last two cases was the 
Fisher‘s exact test (Tab.3). 
Table 2: General characteristics of 96 patients in the study 
 N % 
Patients, total (%) 96 (100) 
   
Sex, n (%)*   
- Females 73 (76) 
- Males 23 (22,9) 
   
Age, mean (+SD)      50,4(+ 12)  
   
Year diagnosis, n (%)   
- From 2003 to 2005 34 (35,4) 
- From 2006 to 2010 62 (64.6) 
   
Tumor size, mean in mm (SD)        5,6 (+ 2,3)  
   
Recurrence, n (%)   
- Yes 8 (8,3) 
- No 88 (91,7) 
   
Extra-capsular spread, n (%)   
- No 84 (87,5) 
- Yes 12 (12,5) 
   
Foci, n (%)   
- Unifocal 85 (88,5) 
- Multifocal 11 (11,5) 
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Lymph nodes, n (%)   
- Not evaluated 69 (71,9) 
- Lymphoadenectomy with L- 18 (18,7) 
- Lymphoadenectomy with L+ 9 (9,4) 
   
B-RAF, n (%)   
- Not performed 63 (65,6) 
- Abesent 26 (27,1) 




Table 3: Risk factors for cancer recurrence 
 
 Presence of recurrence* 
     n/N (%) 
P-value 
Sex   
- Females        5/73 (6.8) 0.43a 
- Males        3/23 (13) 
   
Age   
- 0 to 40        2/22 (9.1) 0.73b 
- 41 to 50        2/26 (7.7) 
- 51 to 60        3/26 (11.5) 
- 61 or more        1/22 (4.5) 
   
Year diagnosis   
- From 2003 to 2005         5/34 (14.7) 0.34
a 
- From 2006 to 2010         3/62(48.3) 
   
Tumor size, in mm   
- 0 to 4         0/33 (0.0) <0.001b 
- 5 to 6         1/26 (38.8) 
- 6 to 7         3/26 (11.5) 
- >7         4/11 (36.4) 
   
Extracapsular spread   
  <0.001
a 
- No         2/84 (2.4) 
- Yes         6/12 (50.0) 
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Foci   
- Unifocal 6/85 (7.1) 0.23a 
- Multifocal 2/11 (18.2) 
   
Lymph nodes     
- Not evaluated 1/69 (1.4) <0.001a 
- Lymphoadenectomy with L- 4/18 (22.2) 
- Lymphoadenectomy with L+ 3/9 (33.3) 
   
B-RAF (n=96)   
- Not performed          5/63 (7.9) <0.01a 
- Abesent          0/26 (0.0) 
- Present          3/7 (42.9) 
   
B-RAF (n=33)   
- Absent          0/26 (0.0) <0.01a 
- Present          3/7 (42.9) 
 
a Fisher‘s exact test, two-sided 
b Chi-square for trend 
Discussion 
Thyroid cancer is one of the most important malignant tumors of 
the endocrine system. Its incidence is increasing over the years, 
approximately 1% of all the new diagnoses of cancer.  Its 
etyology appears to be multifactorial, being due to the 
interaction between environmental factors, among which the 
most important are exposure to radiation and the lack of iodine 
in the diet, and genetic factors. 
The expansion of knowledge about genetic  mutations 
occurrinng in different thyroid tumors has characterized recent  
years, allowing the  identification of a correlation between 
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specific mutations and phenotypic characteristics of thyroid 
cancers.  
An example is represented by BRAF mutation that appears to be 
an indicator of aggressive behavior of PTC. Studies of this 
mutation were later exteded to the development of new targeted 
terapie for thyroid cancer such as the ones represented by 
inhibitors  of RET and BRAF-dependent tyrosine kinase 
activity. 
The results of these trials  should provide us with the therapeutic 
efficacy  of these treatments and their potential use, whether 
developed as monotherapy or as associations of multiple drugs, 
especially in the treatments of aggressiv thyroid tumors.  
The application of genetic research of particular mutations to the 
diagnosis has allowed to improve the cytological diagnosis in 
those samples with FNA cytology indeterminate and/or atipic. 
The identification of BRAF mutation is particularly promising 
since the simple realization and the high specificity of the 
analysis for the determining of malignancy (2).  
Since B-RAF mutation had been first descrive (34) its role in 
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tumorogenesis of papillary thyroid carcinoma has been well 
studied and the specificity of this mutation for PTCs has been 
pointed out.  BRAF mutations are common in thyroid cancer as 
well as in melanomas: this fact can be explained with the role of 
cAMP in cell growth of both melanocytes and thyreocytes. In 
these cell types, cAMP activates MEK1 and extracellular signal-
regulated kinases through mechanisms that may differ but that 
converge on BRAF.  The role of  MAPK pathway in 
pathogenesis of PTC has been well studied elsewere (29,35 ,36) 
first underlined the strong association between BRAF mutation 
and poor prognosis of PTC. A few time after (28) has been 
confirmed that BRAF mutation is specific for cancer arising 
from papillary line, such as classic variant, poorly differentiated 
or anaplastic thyroid carcinomas. Since the potential application 
of mutational analysis of BRAF in thyroid FNAB has been well 
documented (37). Several studies  emphasized that BRAF 
mutation detection in FNAB specimens  can help diagnose and 
identify those patients who may need more aggressive surgical 
treatment and vigilant clinical monitoring (32,38,39) . 
It is important to underline that all studies showed the 
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association between BRAF mutation and increased recurrence 
rate (40) and even mortality  (41). Multivariate analyses showed 
that  the prognostic power of BRAF mutation does not depend 
from classical clinicopathological prognostic factors, such as 
age, capsular invasion, multifocality, lymph node methastases 
(40, 42). These data leaded to investigate the role search of 
BRAF mutation in optimizing the risk management of papillary 
thyroid microcarcinoma, as well as PTCs > 1 cm. Several 
studies, of which two italian (43, 44, 45,) demonstrate the 
association between BRAF mutation and clinicopathological 
aggressiveness of PMTC. However (45) analysis of differential 
BRAF(V600E) mutational status in high aggressive papillary 
thyroid microcarcinoma stated the difficulty to find any case of 
‗‗clinical‘‘ recurrence of PTMC over short follow-up periods, so 
the predictive role of BRAF mutation for the  recurrence of an 
indolent tumour such as PTMC could not be directly 
established. At the moment it is unclear how the ‗‗clinical‘‘ 
recurrence could be defined. A short time of follow-up might be 
one reason for the lack of any recurrence.  
Another explanation for the lack of recurrence might be that the 
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sensitive serum thyroglobulin testing and radioiodine body scan, 
which are worldwide routinely used for the detection of thyroid 
cancer persistence/recurrence  were apparently not used in this 
study for the follow-up of PTC. Nevertheless, the highly  
significant association of BRAF mutation with the classical 
high-risk clinicopathological factors in PTMC demonstrated by 
the study again strongly suggests that, as in conventional PTC, 
BRAF mutation is also a predictor for the aggressiveness of 
PTMC and may therefore indicate a poor prognosis.  Although 
further studies on PTMC are needed to directly test this 
hypothesis, the previous demonstration that BRAF mutation 
predicted PTC recurrence in patients with TNM stage I and II 
diseases (then, a group including several PTMCs) could be 
useful to support it (23,42). 
As PTMC is associated with an extremely low mortality rate, the 
core of the clinical effort in managing this cancer is to prevent, 
identify, and manage its recurrence. Preoperative information of 
BRAF mutation status obtained through analysis of 
ultrasonography-guided fine-needle biopsy specimens of PTMC 
could be very useful in guiding the management of this cancer at 
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various stages, helping determine the extent of surgery, the need 
for radioiodine ablation, and the subsequent follow-up. In recent 
years we have seen a rapid rise in the incidence of thyroid 
cancer worldwide, with a very high increase in Sicily, 
considered at the moment one of most stricked area in the world 
(21). It is unclear if the reason of this increase is an improved 
diagnosis or a real exasperation of the tumour (46, 47). Given 
that PTC accounts for 80% of all thyroid cancers and that nearly 
50% of the new cases of PTC are PTMC, (46,48) a major 
challenge in managing thyroid cancer is how to appropriately 
manage the already large and still increasing number of PTMC 
cases. Although the overall prevalence of BRAF mutation in 
PTC is relatively high, around 45% on average,(49) the 
prevalence of this mutation in PTMC is generally much lower in 
many parts of the world (50, 51,52, 53) and as low as 18% in 
PTMC of 5 mm in size (53). Usually, the prevalence of BRAF 
mutation in PTC with TNM stages I and II, which consist 
largely of small tumors, is around 30% (49). With the relatively 
low prevalence of BRAF mutation in PTMC, it seems feasible to 
treat more aggressively the one-third of PTMC patients that 
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have BRAF mutation and may be thus prone to a poor 
prognosis. The remaining cases (majority) of the PTMC patients 
that are BRAF mutation-negative could be relatively 
conservatively managed unless indicated otherwise by other 
factors. The current risk management of PTMC is virtually 
exclusively based on clinicopathological criteria. By adding 
BRAF mutation as a new dimension in risk stratification of 
PTMC, the appropriate extent of surgical and medical treatments 
of this cancer may now be better determined. 
Our study confirmed the association between well-known risk 
factors, such as multifocality or lymph node involvement and 
recurrence of disease. The limited number of thyroid multifocal 
microcarcinoma  not allowed us to find a clear association 
between this specific risk factor and disease relapse. On the 
contrary, the size of tumour seems to be strictly correlated to this 
risk: infact, we had never obsesved a relapse for tumors < 5 mm, 
a low incidence for tumors between 5 and 6 mm of diameter 
(3.8%) and a progressive increase of risk as far as tumors > 7 
mm, that showed a recurrence in 4/11 cases (36,4%). 
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An important association has been found between B-Raf 
mutation and risk of recurrence: in 3/7 patients presenting the 
mutation a relapse was observed, while none of 26 patients 
having a B-Raf wild type expressed the recurrence. It should 
rather be underlined the low incidence of B-Raf mutation in the 
total amount of thyroid microcarcinomas (only 7 patient out of 
33 sampling showed the mutation). On the other hand it should 
be acknowledged that thyroid microcarcinoma is largely 
diagnosed incidentally. As a consequence, it is not usual to 
perform a fine-needle aspiration biopsy in the presence of an 
infracentimetric thyroid nodule, then the search of B-Raf 
mutation in thyroid nodules < 10 mm cannot be considered a 
routinary practice. In spite of that, we aim to perform fine-
needle aspiration biopsies in the presence of  thyroid nodules 
having suspected pattern, such as irregular edges, intralesional 
microcalcifications and/or vascularization, and a diameter of 5 
mm at least. This behavior led us to two major evident results: 
an improved possibility to obtain a correct preoperative 
diagnosis; a precise prognostic statement. 
The impact of medical and surgical interventions on the survival 
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of patients with PTMC is a topic widely discussed and there are 
many controversies about the management (1). 
According to the authors overall actuarial survival rates, at 10 
and 15 years, are 96.6% and 96.3%, respectively. In their 
experience increasing age was the only statistically important 
predictor for disease-specific survival (p = 0.001). Neither the 
type of surgery (total thyroidectomy, near-total/subtotal 
thyroidectomy or lobectomy), nor the radiometabolic treatment 
has any impact on excellent prognosis of patients with PTMC. 
The Authors conclude, that patients lacking evidence of 
metastatic disease may undergo lobectomy alone (54). The 
concept of limited surgery is supported also by many other 
Authors (54,55, 56). Bilimoria et al.(56) analysed almost 40,000 
patients from the National Cancer Data Base with papillary 
thyroid carcinoma and concluded that the treatment of choice for 
patients with a tumour less than 1 cm is thyroid lobectomy (56). 
Some Authors are of the opinion, that surgery, even if limited, 
may not be the first step of treatment (12). Ito et al. (57) selected 
low-risk patients with PTMC and, during 5 years‘follow-up, 
only 6.7% of these patients were confirmed as showing an 
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increase in size at US compared to baseline findings. None 
developed additional distant metastasis or died of thyroid 
carcinoma. The Authors conclude that surgical treatment after 
the appearance of carcinoma progression is not late (57). 
On the other hand, PTMC is often multifocal; the range of 
multiple non-contiguous tumour foci is between 18 and 87%, 
depending upon the technique used for the pathological analysis 
(102). The genetic studies, which compared the specific patterns 
of monoclonal X-chromosome inactivation (58) and distribution 
of BRAF mutation (59) demonstrated that the individual tumour 
foci often arise as independent tumours and, indeed, that they 
can grow and spread. 
Fundamental for future clinical purposes is to determine clinical 
and especially molecular parameters which would define small 
groups of PTMC with aggressive biological behaviour. The most 
promising genetic is determination preoperative of BRAF 
mutation. 
It could help to determine the choice of therapeutic management 
of this cancer and to assess the extent of initial surgical 
treatment and the need for radioiodine ablation (7).  
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In oncology, since alterations of BRAF are widely represented in 
many solid tumos it is the considerable interest directed to the 
development of specific inhibitors of BRAF activity (28). 
Among these , the best known is the biaryl urea BAY 43-9006 
(sorafenib) (60); it is an inhibitor active against RAF 
multikinase and other proteinkinase (VEGGFR-2and PDGRF), 
with can effectively block the kinase activity of BRAF (24, 
61).The BAY 43-9006 has been  tested on several types of 
human carcinomas including the thyroid cancer, and preliminary 
results showed a  minimal or partial responce in some patients 
(62).  
Conclusion 
The present study allowed us to reach the following conclusions: 
1)We corroborate the reliability of "classic" risk factors for the 
papillary thyroid carcinoma, expecially extracapsular spread and 
lymph node involvement, that showed to be significantly 
associated to a poor prognosis. also in microcarcinomas; 
2)We esteem that it should be better fixed the limit of size 
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defining a low risk class of papillary thyroid carcinoma: infact, 
we observed that a diameter > 7 mm is related to a prognosis 
similar to papillary thyroid carcinomas > 1 cm. So, it seems that 
the risk stratification in the category of "microcarcinoma" is 
continuously growing with a tendence to reach the risk of larger 
tumors. 
3)The search of B-RAF V600E mutation in samples of FNAB of 
thyroid nodules ≤ 1 cm showed to be reliable in terms of 
diagnostic power and prognostic significance. Concerning the 
first item, we would underline that it has been proved, in our 
study as well as in the current scientific literature the 
improvement of diagnonstic sensitivity and specificity of the 
evaluation of B-RAF V600E mutation to identify malignancies 
in thyroid nodules, expecially if ≥ 5 mm.  
We would clarify that the meaning of "recurrence" in our 
experience is not a real progression of disease. Concerning a 
tumor having an indolent behavior, such as papillary thyroid 
carcinoma, the recurrence should be considered a biochemical-
imaging evidence of residual-recurrent thyroid tissue after 
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thyroidectomy for malignancy. In spite of that, this tissue is 
sensitive to usual tratments, such as radioiodine, and after a new 
radiometabolic treatment the thyroglobulin as well as 
radionuclide fixation of thyroid bed usually shows an 
improvement and even a disappearance of disease signs. 
The finding of this mutation in samples of thyroid FNAB is 
associated to a poor prognosis. It could lead to  more aggressive 
attitudes in terms of diagnosis, treatment and postoperative 
immediate and late controls. 
A longer follow up is needed to confirm these findings and to 
identify a cathegory of patients involved in a real recurrence of 
disease. 
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